Richard Aranda
Chief Tech/Sci/R&D Officer presso GOSSAMER BIO, INC.
Patrimonio netto: 234 583 $ in data 31/03/2024
Profilo
Richard Aranda is currently the Chief Medical Officer at Gossamer Bio, Inc. He previously worked as the Vice President-Clinical Development at Receptos LLC from 2015 to 2018, the Vice President-Medical Science & Inflammation at Novo-Nordisk Biochem, Inc. from 2011 to 2015, and as a Principal at Bristol Myers Squibb Co. from 2001 to 2011.
Dr. Aranda obtained his undergraduate degree from the University of California, Santa Cruz and holds doctorate degrees from Stanford University School of Medicine and Stanford School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GOSSAMER BIO, INC.
0.09% | 18/03/2024 | 198 799 ( 0.09% ) | 234 583 $ | 31/03/2024 |
Posizioni attive di Richard Aranda
| Società | Posizione | Inizio |
|---|---|---|
| GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Precedenti posizioni note di Richard Aranda
| Società | Posizione | Fine |
|---|---|---|
| RECEPTOS INC | Corporate Officer/Principal | 01/01/2018 |
| Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01/01/2015 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/05/2011 |
Formazione di Richard Aranda
| University of California, Santa Cruz | Undergraduate Degree |
| Stanford School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
| Novo-Nordisk Biochem, Inc. |
- Borsa valori
- Insiders
- Richard Aranda
